Skip to main content
Fig. 2 | Trials

Fig. 2

From: Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial

Fig. 2

Detailed study schedule. 1Blood pressure, heart rate, weight and height. 2Pen and paper headache dairy. 3Migraine Disability Questionnaire (Migraine Disability Assessment (MIDAS)) and Headache Impact Test (HIT), German versions, standard questionnaires for assessing the extent of migraine-related disability. 4Blood beta-hydroxybutyrate and glucose levels, measured with a portable ketone meter (precision xtra by Abbot). 5Routine laboratory (renal and liver function tests, electrolytes, full blood count, C-reactive protein, serum cholesterol, triglycerides, serum proteins, albumin, glucose, Hba1c, insulin, cortisol, lactate, TSH, FT4 and FT4). 6Blood draw (1 × EDTA, 1 × PAXgene) at each time point for genetic profiling and gene expression analysis using microarrays. 7Blood draw at each time point for oxidative and nitrosative stress markers (malondialdehyde (MDA), carbonylated proteins, nitrite, nitrotyrosine) and serum cytokine measurements (including, but not limited to, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, MCP-1, TNF-α, TNF-β, TGF-β1). V = visit

Back to article page